Results
1 -
10 of
13
(Click
here to explore results)
- Epigenetics for Drug Discovery, CHAPTER 5 Targeting Histone Acetylation. Daniel Vitt, Roland Baumgartner, Hella Kohlhof
, 2016
, Pages 96-126
- Epigenetics for Drug Discovery, CHAPTER 9 Who will Benefit from Epigenetic Drugs?. Dominique Verhelle, David J. Shields
, 2016
, Pages 230-248
- Anti-aging Drugs: From Basic Research to Clinical Practice, CHAPTER 5 Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Ramón Cacabelos, Juan Carlos Carril, Oscar Teijido
, 2017
, Pages 75-141
- Macrocycles in Drug Discovery, CHAPTER 4 Macrocyclic Inhibitors of Zinc-dependent Histone Deacetylases (HDACs). A. Ganesan
, 2015
, Pages 109-140
- Orphan Drugs and Rare Diseases, Chapter 11 Drug Discovery Approaches for Rare Neuromuscular Diseases. Graham M. Wynne, Angela J. Russell
, 2014
, Pages 257-343
- Epigenetics for Drug Discovery, CHAPTER 10 Dosing – When Less is More. Kurinji Pandiyan, Peter A. Jones, Stephen B. Baylin
, 2016
, Pages 249-266
- Epigenetics for Drug Discovery, Subject Index
, 2016
, Pages 316-321
- Anti-aging Drugs: From Basic Research to Clinical Practice, CHAPTER 21 HDAC Inhibitors: A New Avenue in Anti-Aging Medicine. E. G. Pasyukova, A. M. Vaiserman
, 2017
, Pages 514-534
- Epigenetics for Drug Discovery, CHAPTER 4 Targeting DNA Methylation. Tom D. Heightman, Michael McCullar
, 2016
, Pages 68-95
- Epigenetics for Drug Discovery, CHAPTER 12 Safety Considerations for Epigenetic Mechanisms as Drug Targets: Are Existing Toxicology Studies Fit for Purpose?. Paul Butler, Michael Lawton, Robert E. Chapin, Brett D. Hollingshead, Karen Leach, Prashant R. Nambiar, Mathew Pletcher, Amy H. Yang
, 2016
, Pages 288-315